NSC 57148 is a selective Grb7 SH2 domain antagonist with an IC 50 value of 1.1 μM. NSC 57148 reduces cancer cell proliferation and migration. NSC 57148 is promising for research of Grb7-overexpressing malignancies such as breast and pancreatic cancers.
Products | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > EGFR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.